Ulcerative Colitis IND Trial Application Cleared by FDA for InDex’s Cobitolimod

Ulcerative Colitis IND Trial Application Cleared by FDA for InDex’s Cobitolimod
The U.S. FDA has cleared InDex Pharmaceuticals AB’s Investigational New Drug (IND) application to launch a Phase 2b clinical trial for cobitolimod (Kappaproct) in patients with moderate to severe ulcerative colitis (UC). Cobitolimod is the the Stockholm, Sweden-based company’s lead drug candidate, now in late-stage clinical development for moderate to severe ulcerative colitis. UC is a chronic

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

3 comments

  1. Cecilia Follens says:

    Please can I have more information.. I am from South Africa and is struggling with UC. I am on Humira, Assacol,Cortisone, Denol and still struggling….. Regards Cecilia Follens

    • Tim Bossie says:

      Cecilia, we are working hard to continue to provide the most relevant, accurate and timely information for people who suffer with UC like you. 🙂

Leave a Comment

Your email address will not be published. Required fields are marked *